{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 61 of 92', 'CR845-CLIN3103', 'placebo), depending on the dose of active study drug (0.5 mcg/kg, 1.0 mcg/kg, 1.5', 'mcg/kg).', 'Given a sample size of 350 patients (175 per treatment group) and assuming a true', 'response rate of 30% for the placebo group and a true response rate of 50% for the', 'CR845 group (defining response as an improvement from baseline >3 points with respect', 'to the Worst Itching Intensity NRS at Week 12), a 2-sided continuity corrected', 'Chi-square will have 96% power to detect a treatment difference. The power of this test', 'statistic would be 84% for differences from placebo as low as 0.16 (Table 4).', 'Table 4.', 'Power as a Function of Effect Size (N = 175 per arm)', 'Placebo Response', '0.30', '0.30', '0.30', '0.30', 'CR845 Response', '0.50', '0.48', '0.46', '0.45', 'Odds Ratio', '2.333', '2.154', '1.988', '1.909', 'Power', '96%', '92%', '84%', '79%', 'a.', 'Power for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error.', 'Based on results of a planned interim assessment, the sample size may be increased up to', '500 patients (250 per treatment group). Given this maximum sample size, and assuming', 'a true response rate of 30% in the placebo group, a 2-sided continuity corrected', 'Chi-square would have approximately 90% power to detect a treatment difference when', 'the CR845 response rate is 45% (a 15% difference from placebo) (Table 5).', 'Table 5.', 'Sample Size as a Function of Odds Ratio (90% Power)', 'Placebo Response', '0.30', '0.30', '0.30', '0.30', '0.30', 'CR845 Response', '0.50', '0.48', '0.46', '0.45', '0.44', 'Odds Ratio', '2.333', '2.154', '1.988', '1.909', '1.833', 'Sample Sizea', '134', '164', '204', '230', '262', 'a.', 'Sample size for a 2-sided Chi-square continuity-corrected test and a 5% Type 1 error.', '8.3', 'Randomization', 'Before the start of the study, a computer-generated randomization schedule will be', 'prepared. Randomization will be performed using an IVRS/IWRS. Patients will be', 'randomized in a 1:1 ratio to receive either CR845 0.5 mcg/kg IV or matching placebo IV', 'during the Double-blind Treatment Period. Patients will be stratified according to their', 'use or non-use of concomitant medications to treat their itch during the week prior to', 'randomization (Run-in Period) as well as the presence or absence of specific medical', 'conditions. These medical conditions include:', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 62 of 92', 'CR845-CLIN3103', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental status or', 'disorientation', 'Gait disturbance or movement disorder', 'All eligible patients will receive CR845 at a dose of 0.5 mcg/kg starting on Day 1 of the', 'Open-label Extension Phase.', '8.4', 'Interim Analysis', '8.4.1', 'Sample Size Re-estimation', 'An unblinded interim analysis for sample size re-estimation will be conducted when', 'approximately 50% of the first 350 patients have been randomized and have either', 'completed the 12-week Double-blind Treatment Period or have discontinued from', 'double-blind treatment early. The planned interim assessment will be conducted by an', 'IDMC. An unblinded statistician who will not be part of the study team will provide', 'results of the interim analysis to the IDMC members. Members of the IDMC will not', 'participate in the Data Safety Monitoring Board (DSMB) and will not be members of the', 'study team. During the interim assessment, the study team will remain blinded to the', 'data; however, the IDMC will receive unblinded summary results to implement the', 'decision rule for sample size re-estimation. The IDMC will only communicate the', 'decision to either keep the original sample size or to increase it; no other results will be', 'provided to blinded staff. The DSMB will be made aware of the decision, but not given', 'the results that were the basis of the decision.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}